Analyst firms · Oppenheimer · OVID
Oppenheimer OVID price target and rating history
Ovid Therapeutics Inc. (OVID) · Health Care
Oppenheimer rates Ovid Therapeutics Inc. (OVID) Outperform with a $7 price target, as of its latest action on Oct 9, 2025. It has published 3 rating actions on OVID since October 2023, including 0 upgrades and 1 downgrade. Across 3 firms with a OVID price target in the last 12 months, the median target is $5.
- Current rating
- Outperform
- Price target
- $7
- Median target, all firms
- $5
- Actions on OVID
- 3
Oppenheimer price target on OVID
Every Oppenheimer rating on OVID
- Oct 9, 2025
- Jun 18, 2024
- Oct 13, 2023
How other firms rate OVID
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| Wolfe Research | Outperform | $5 | Oct 15, 2026 |
| Cantor Fitzgerald | Overweight | Oct 9, 2026 | |
| Guggenheim | Buy | $7 | Oct 6, 2026 |
| Roth Capital | Buy | $3 | Dec 11, 2025 |
| Leerink Partners | Outperform | Nov 17, 2025 |
Questions about Oppenheimer and OVID
- What is Oppenheimer's price target for OVID?
- Oppenheimer's latest stated price target for Ovid Therapeutics Inc. (OVID) is $7, from its action on Oct 9, 2025.
- What is Oppenheimer's rating on OVID?
- Oppenheimer rates OVID Outperform, a bullish rating, as of Oct 9, 2025.
- When did Oppenheimer last change its view on OVID?
- On Oct 9, 2025, Oppenheimer starts coverage at Outperform, price target $7.
- How does Oppenheimer's OVID target compare with other analysts?
- Across 3 firms with a OVID price target in the last 12 months, the median target is $5.
All Oppenheimer ratingsOVID news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.